Detalles de la búsqueda
1.
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis.
Pharm Res
; 40(11): 2653-2666, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38082089
2.
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis.
Allergy
; 77(11): 3388-3397, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35815904
3.
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis.
Acta Derm Venereol
; 102: adv00726, 2022 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35393631
4.
Connexin hemichannels influence genetically determined inflammatory and hyperproliferative skin diseases.
Pharmacol Res
; 99: 337-43, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26211951
5.
The human Cx26-D50A and Cx26-A88V mutations causing keratitis-ichthyosis-deafness syndrome display increased hemichannel activity.
Am J Physiol Cell Physiol
; 304(12): C1150-8, 2013 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23447037
6.
Pathological hemichannels associated with human Cx26 mutations causing Keratitis-Ichthyosis-Deafness syndrome.
Biochim Biophys Acta
; 1818(8): 2014-9, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21933663
7.
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Am J Clin Dermatol
; 24(3): 469-483, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36808602
8.
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years.
Dermatol Ther (Heidelb)
; 13(9): 1987-2000, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37480432
9.
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Paediatr Drugs
; 25(1): 67-77, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36529811
10.
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 13(11): 2697-2719, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37750994
11.
Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin.
J Allergy Clin Immunol Pract
; 11(5): 1421-1428, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36958520
12.
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 12(7): 1501-1533, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35596901
13.
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.
Dermatol Ther (Heidelb)
; 12(12): 2731-2746, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36269503
14.
Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis.
J Allergy Clin Immunol Pract
; 10(5): 1279-1285.e1, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35032695
15.
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Am J Clin Dermatol
; 23(3): 393-408, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35503163
16.
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
Paediatr Drugs
; 23(5): 515-527, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462864
17.
Comparison of respiratory motion artifact from craniocaudal versus caudocranial scanning with 64-MDCT pulmonary angiography.
AJR Am J Roentgenol
; 195(1): 155-9, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20566810
18.
Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter].
Immunotargets Ther
; 12: 77-78, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256021
19.
Publisher Correction to: Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Am J Clin Dermatol
; 24(4): 673, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37193879
20.
Aberrant connexin26 hemichannels underlying keratitis-ichthyosis-deafness syndrome are potently inhibited by mefloquine.
J Invest Dermatol
; 135(4): 1033-1042, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25229253